)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Enorama Pharma
Enorama Pharma (ERMA) investor relations material
Enorama Pharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary19 Aug, 2026
Executive summary
The period was marked by significant regulatory and financial challenges, including a Refuse-to-File decision from the FDA regarding PMTA applications for NIC-S® in the US, leading to legal proceedings and a control balance sheet due to capital erosion.
The company continued to invest in regulatory studies and legal actions to support the PMTA process, while also focusing on cost efficiency and product development for new markets.
Leadership changes occurred post-period, with Amy Walker appointed as interim CEO following the resignation of Bengt Jönsson.
Financial highlights
Net sales for Q2 2026 were 0 KSEK, down from 733 KSEK in Q2 2025; for H1 2026, net sales were -109 KSEK, compared to 1,182 KSEK in H1 2025, due to product returns.
Operating loss for Q2 2026 was -11,707 KSEK (Q2 2025: -15,321 KSEK); for H1 2026, -22,584 KSEK (H1 2025: -31,999 KSEK).
Pre-tax loss for Q2 2026 was -13,115 KSEK (Q2 2025: -18,708 KSEK); for H1 2026, -25,761 KSEK (H1 2025: -41,219 KSEK).
Earnings per share for Q2 2026 were -0.18 SEK (Q2 2025: -0.28 SEK); for H1 2026, -0.35 SEK (H1 2025: -0.61 SEK).
Cash flow for Q2 2026 was -14,973 KSEK (Q2 2025: -4,204 KSEK); for H1 2026, 290 KSEK (H1 2025: -6,899 KSEK).
Cash and cash equivalents at June 30, 2026, were 2,098 KSEK (June 30, 2025: 2,518 KSEK).
Outlook and guidance
The company remains committed to pursuing the PMTA process for NIC-S® in the US, despite ongoing regulatory and legal uncertainties.
Efforts continue to restore equity and secure liquidity, with optimism for the brand's future in the US and new European and online markets.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Enorama Pharma
- Losses persist as regulatory hurdles in the US drive negative equity and legal action.ERMA
Q1 2026 - Heavy losses and a full US subsidiary write-down after FDA setback; US focus remains.ERMAQ4 2025
- Net sales dropped sharply and losses deepened as US distributor transition delayed revenue.ERMAQ3 2025
- Sharp revenue decline and deepening losses in H1 2025 amid US transition and PMTA focus.ERMAQ2 2025
- Net sales rose sharply and losses narrowed as US pouch sales accelerated.ERMAQ3 2024
- US pouch sales drove revenue growth and improved liquidity, with narrowed losses.ERMAQ2 2024
- Losses deepened as Enorama Pharma restructures for US white snus growth and seeks new funding.ERMAQ1 2025
- Revenue growth reversed in Q4 as US sales fell and NRT assets were fully written down.ERMAQ4 2024
Next Enorama Pharma earnings date
Q3 202618 Nov, 2026
Enorama Pharma
Next Enorama Pharma earnings date
Q3 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Enorama Pharma AB is a pharmaceutical company headquartered in Malmö, Sweden. The company focuses on developing and manufacturing medicated chewing gum and other nicotine products. Its main products include nicotine chewing gums and pouches aimed at aiding smoking cessation. Enorama Pharma also explores other applications such as medical cannabis chewing gums and oromucosal drug delivery systems. The company operates with a commitment to providing innovative pharmaceutical solutions. Enorama Pharma is listed on the Stockholm Stock Exchange.